Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash from Financing Activities (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Cash from Financing Activities for 7 consecutive years, with -$3.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 10.0% to -$3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.0 million through Dec 2025, up 17.71% year-over-year, with the annual reading at -$9.0 million for FY2025, 17.71% up from the prior year.
  • Cash from Financing Activities hit -$3.0 million in Q4 2025 for Harmony Biosciences Holdings, down from -$3.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $7.1 million in Q4 2021 to a low of -$55.1 million in Q3 2023.
  • Historically, Cash from Financing Activities has averaged -$5.6 million across 5 years, with a median of -$345500.0 in 2023.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 11425.0% in 2022 and later plummeted 2787.76% in 2023.
  • Year by year, Cash from Financing Activities stood at $7.1 million in 2021, then tumbled by 62.42% to $2.7 million in 2022, then tumbled by 2113.66% to -$53.5 million in 2023, then surged by 94.88% to -$2.7 million in 2024, then fell by 10.0% to -$3.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for HRMY at -$3.0 million in Q4 2025, -$3.0 million in Q3 2025, and -$2.7 million in Q2 2025.